Canada markets closed

Imagin Medical Inc. (IME.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
0.47000.0000 (0.00%)
At close: 3:50PM EDT
Sign in to post a message.
  • A
    Anonymous
    Seeing some green in their chart at the moment, lot of short term indicators are positive- would be nice to see some kind of movement. Have been following the reports from SmallCapCanada, they deliver quality profiles on Canadian companies showing strong signs of a breakout run- great resource for investors, check it out.
  • D
    Dave
    VANCOUVER, British Columbia and BOSTON, April 26, 2018 (GLOBE NEWSWIRE) -- Imagin Medical (CSE:IME) (OTC PINK:IMEXF) (Frankfurt & Stuttgart Symbol:DPD2) (the “Company”) is providing the following update on the Company’s current activities.
    The recent closing of a Private Placement for approximately $4,000,000 reinforces Imagin’s financial runway, enabling the Company to progress through the next critical steps toward product commercialization. Imagin’s management team has been strengthened with the recent appointments of a new CFO and Director of Regulatory Affairs who add the essential experience and knowledge base in the medical device industry to drive the Company through several paths concurrently.

    To date, five subjects have been evaluated using the i/Blue System. Given that this study is the i/Blue system’s initial use in a human bladder, approximately two weeks have been allowed between procedures for the development team to assess performance and to make hardware improvements, such as lenses and filters, as well as software adjustments. More subjects will be scheduled for evaluation, and further updates will be issued. The data and knowledge Imagin is acquiring is essential in refining the images that the company believes will lead to optimal performance.

    Simultaneously, the Company continues to work with Optel, Inc. on the product redesign for future clinical trials and commercialization. The miniaturization process will add significant imaging capability and lower the actual cost of the product. In addition, documentation for federal regulatory approval continues in anticipation of meetings expected to take place during the summer months.

    “This is an exciting time. With proper funding and an experienced management team in place, we’re confident 2018 will be a pivotal year,” said Jim Hutchens, Imagin’s President and CEO.
  • s
    slinger
    Began clinical patient studies this week.
  • s
    slinger
    I/Blue functioning unit completed
  • D
    Dave
    We need a little news to get this moving up!
  • s
    slinger
    VANCOUVER, British Columbia and BOSTON, July 17, 2018 (GLOBE NEWSWIRE) -- Imagin Medical (CSE:IME) (IMEXF) (DPD2.F) (DPD2.SG) (“Imagin” or the “Company”) announced today favorable results in the 10-subject investigator-sponsored research study being conducted at the University of Rochester Medical Center using the i/Blue Imaging System (the “URMC Research Study”), an important step in the development of a commercially-viable product.

    In the URMC Research Study, fluorescence was successfully demonstrated in 15 minutes, confirming that the i/Blue Imaging System will potentially allow physicians to “see” bladder cancer significantly faster than the full hour or more required by currently available imaging technology.

    “While a backorder on certain component parts needed to make system adjustments during the URMC Research Study caused some delay, we are obviously very pleased with the outcome,” said Jim Hutchens, Imagin’s President and CEO. “This is an exciting time. We believe that the i/Blue Imaging System holds great promise for improving physicians’ ability to detect cancer and visualize the surgical field where endoscopes are used. To that end, we look forward to updating our stakeholders as we progress.”
  • W
    Walter
    Up 30%, may be some positive news coming.
  • A
    Anonymous
    It's as simple as this: IF management can execute, and the word out about their existing discovery/ product
    IF they can establish their IP (intellectual property) as the basis for a new standard of care in diagnosing bladder cancer, then it's not a great leap of faith to assume this same technique can be used on a variety of other cancers, including colon cancer. It's highly likely that the manufacturers of colonoscopy systems are going to want to ADD this new technique to their arsenal of tools in diagnosing cancer in the earliest of stages and also to ward of market share loss from the purveyors of "stool DNA" technologies that have less than a 70% specificity in diagnosing pre cancerous lesions. Move forward 2-3 years with advancements leading to the diagnosis of other forms of cancer and we are looking at a 500 million dollar company. Hold onto your shares in this tiny micro cap stock. The leverage you acquire now just may see you into a comfortable retirement.
  • G
    Geoff
    They spent about $1.8 million in the last quarter report. They said they had $900,000 left at the end of MARCH. Now it is almost 3 months later. I expect them to have to raise money and a lot of it as there are no human clinical trials going on now according to the company. They have authorization to issue many shares but really who on earth would buy them? even for half a cent! They are miles away from selling a product and a company that wants the tech can just buy it in bankruptcy and hire on the current staff. In my opinion!
  • R
    Robert
    PRIVTE PLACEMENT results: raised $1,914,000 on the sale of 38,280,000 shares. Add that to $2.3 million we started the year with and we have a bank account of about $4,214,000. That should see us through FDA approval. In addition, the PPs warrants of 38,280,000 are worth 15 cents each to Imagin, which is as much #$%$7 million. That could be a good start on product rollout. I am guessing that a buyout candidate might be attracted by an acquisition that can pay its own way. Though the warrants expire within two years of issue, there is fine print in the offer that says Imagin can shorten that time to as short as 30 days to redeem if stock is selling at 25 cents, or more, for more than 10 days.
  • D
    Dave
    There is news today, I’m not sure can someone tell me if it’s good or bad?
  • N
    Nova461
    This is pushed way out and why they pulled the timeline chart from the company presentation. Clinical trials can't start until the Verified unit is finished which they say may be done by Optel in Mar 2019. Then studies may begin by June 2019. FDA application comes after the outcome of the clinical trials which may not finish until Mar 2020 or later. Hopefully the results are positive. They already stated the FDA process is 12mos or longer so won't happen until Mar 2021 or after. Then production can start if they have contract manufacturing ready which costs big money.

    They will require more rounds of share offerings because the $6M won't come close to lasting that long. If they have to raise money at 5c-7c the share count is really going to balloon.

    The other wild card is there are several competing technologies that are much cheaper that will be ready by then or sooner so they will have competition.

    Getting harder to predict the future outcome now with the long slip in schedule. They haven't met a date yet. Trust has become a real issue here.
  • D
    Dave
    We are now going the right way, hopefully more investors will see the value of the stock at its current price!
  • D
    Dave
    So far, so good!
  • G
    Geoff
    1 for 20 reverse split! and toxic financing! Its over peeps. Reverse splits to pump up the share price almost never work. The share price just drifts lower and lower because people know the company is near the end. IN my opinion.
  • D
    Dave
    Excellent finish yesterday, let’s do it again today!
  • s
    slinger
    Key investment risks removed, high investment return potential
    • Disruptive cutting edge imaging technology will dramatically reduce bladder cancer recurrence rates addressing $1B growing global market
    • Limited R&D risks as concept is proven – this is an execution play
    • Experienced medical device management team that has done it before
    • Management in medical device field for over 30 years
    • Worked together in previous companies
    • High-margin product with strong clinical and economic advantages
    • Commercial launch expected in 2018 with positive operating cash flows
    • Strong acquisition market
    • Most medical device companies grow by acquisition, not organically
    • Company expected to have significant value with multiple liquidity options
  • W
    Walter
    Congrats to Imagin for the very positive news yesterday and continuing quick progress.
  • G
    Geoff
    Most Urologists say blue light is totally unnecessary and using it does not effect their treatment regime one bit. You have an essentially niche technology already dominated by Olympus and Stryker, 2 mega surgical companies with HUGE installed base of equipment and HUNDREDS of dedicated OR sales reps. You have no chance EVEN IF you were not already out of money or soon to be out based on the cash burn rate reported in past quarters. I have no idea how they are even still in business my projections say they ran out of money a month ago. I expect to soon hear about bankruptcy or massive dilution. In my opinion.